Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Québec, Canada.
Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia.
Gastroenterology. 2023 May;164(6):953-965.e3. doi: 10.1053/j.gastro.2023.01.028. Epub 2023 Feb 1.
BACKGROUND & AIMS: Acute pancreatitis (AP) is a complex disease and the leading cause of gastrointestinal disease-related hospital admissions. Few therapeutic options exist for AP prevention. Blood proteins with causal evidence may represent promising drug targets, but few have been causally linked with AP. Our objective was to identify blood proteins linked with AP by combining genome-wide association meta-analysis and proteome-wide Mendelian randomization (MR) studies.
We performed a genome-wide association meta-analysis totalling 10,630 patients with AP and 844,679 controls and a series of inverse-variance weighted MR analyses using cis-acting variants on 4719 blood proteins from the deCODE study (N = 35,559) and 4979 blood proteins from the Fenland study (N = 10,708).
The meta-analysis identified genome-wide significant variants (P <5 × 10) at 5 loci (ABCG5/8, TWIST2, SPINK1, PRSS2 and MORC4). The proteome-wide MR analyses identified 68 unique blood proteins that may causally be associated with AP, including 29 proteins validated in both data sets. Functional annotation of these proteins confirmed expression of many proteins in metabolic tissues responsible for digestion and energy metabolism, such as the esophagus, adipose tissue, and liver as well as acinar cells of the pancreas. Genetic colocalization and investigations into the druggable genome also identified potential drug targets for AP.
This large genome-wide association study meta-analysis for AP identified new variants linked with AP as well as several blood proteins that may be causally associated with AP. This study provides new information on the genetic architecture of this disease and identified pathways related to AP, which may be further explored as possible therapeutic targets for AP.
急性胰腺炎(AP)是一种复杂的疾病,也是导致胃肠道疾病相关住院的主要原因。目前针对 AP 的预防治疗方法有限。具有因果证据的血液蛋白可能代表有前途的药物靶点,但与 AP 相关的血液蛋白很少。我们的目标是通过结合全基因组关联荟萃分析和全蛋白质组孟德尔随机化(MR)研究,鉴定与 AP 相关的血液蛋白。
我们进行了一项全基因组关联荟萃分析,共纳入了 10630 例 AP 患者和 844679 例对照者,以及使用 deCODE 研究中 4719 种血液蛋白的一系列反方差加权 MR 分析(N=35559)和 Fenland 研究中 4979 种血液蛋白的分析(N=10708)。
荟萃分析确定了 5 个位点(ABCG5/8、TWIST2、SPINK1、PRSS2 和 MORC4)的全基因组显著变异(P <5×10)。全蛋白质组 MR 分析鉴定了 68 种可能与 AP 因果相关的独特血液蛋白,其中 29 种蛋白在两个数据集均得到验证。这些蛋白的功能注释证实了许多在代谢组织中表达的蛋白与消化和能量代谢有关,如食管、脂肪组织和肝脏以及胰腺的腺泡细胞。遗传共定位和对可用药基因组的研究也确定了 AP 的潜在药物靶点。
这项针对 AP 的大型全基因组关联研究荟萃分析确定了与 AP 相关的新变异以及与 AP 可能因果相关的几种血液蛋白。本研究提供了关于这种疾病遗传结构的新信息,并确定了与 AP 相关的途径,这些途径可能作为 AP 的潜在治疗靶点进一步探索。